ADCETRIS® (brentuximab vedotin)

ADCETRIS is approved in more than 65 countries, including Brazil, Japan, the United States and countries in the European Union.

Seattle Genetics has U.S. and Canadian commercialization rights to ADCETRIS. Click here to visit the company's website.

US Healthcare Providers
Please click here for the Product Website and click here for the Full Prescribing Information.

Ex-US Healthcare Providers
Please click here for the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information.